GlassScriptPhysician profile
Michael J Troy
NPI 1184613242
$2,950.20
in general payments reported to CMS, 2019-2025
30 companies · $260 in 2025
The $260 reported for 2025 was more than what a typical Obstetrics & Gynecology provider received nationally (typical 2025 total: $158).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $872 · 2020: $278 · 2021: $70.54 · 2022: $782 · 2023: $421 · 2024: $267 · 2025: $260.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $895 · Education: $53.40.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $894.62 |
| Education | $53.40 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $797.00 | 2019-2023 | Lo Loestrin Fe |
| Mayne Pharma Commercial LLC | $328.57 | 2022-2025 | |
| Millicent US INC | $172.80 | 2019-2025 | Intrarosa, Femring, Femlyv |
| Shield Therapeutics INC | $157.39 | 2023-2024 | Accrufer |
| Coopersurgical, INC. | $141.86 | 2019-2022 | |
| Merck Sharp & Dohme LLC | $139.22 | 2019-2022 | |
| Therapeuticsmd, INC. | $127.22 | 2019-2022 | |
| Organon LLC | $126.23 | 2021-2025 | Nexplanon |
| Mallinckrodt Enterprises LLC | $124.99 | 2019 | |
| Exeltis, USA INC. | $110.86 | 2019-2024 | Slynd |
| Astellas Pharma US INC | $99.22 | 2020-2025 | Veozah |
| Pfizer INC. | $94.32 | 2019-2023 | |
| Ethicon US, LLC | $93.03 | 2019-2022 | |
| Avion Pharmaceuticals | $73.89 | 2020-2022 | |
| Myovant Sciences INC. | $61.29 | 2022 |
Show all 29 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Biogen, INC. | $37.95 | 2025 | Zurzuvae |
| Lupin INC. | $34.44 | 2019-2020 | |
| Dexcom, INC. | $27.73 | 2025 | Dexcom G6 Transmitter |
| Agile Therapeutics, INC. | $27.21 | 2022 | |
| Urovant Sciences INC | $23.78 | 2022 | |
| Minerva Surgical, INC | $23.43 | 2019 | |
| Pacira Pharmaceuticals Incorporated | $19.68 | 2024 | Exparel |
| Exact Sciences Corporation | $17.62 | 2025 | The Cologuard Plus Collection Kit |
| Alexion Pharmaceuticals, INC. | $17.55 | 2022 | |
| Scynexis, INC. | $17.50 | 2022 | |
| Sumitomo Pharma America, INC. | $17.35 | 2025 | Myfembree |
| Meditrina | $14.42 | 2025 | |
| Ferring Pharmaceuticals INC. | $13.16 | 2019 | |
| Acessa Health INC. | $10.49 | 2019 |
1 company reported research payments only; those appear in the research section below.
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
Research and ownership
$2.00 in ownership or investment interests, as reported to CMS. These are holdings a clinician or an immediate family member has in a company, not payments received.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Michael Troy listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.